Modern Treatment Strategies: A Shifting Standard

For decades, treatment for pleural mesothelioma changed very little. However, we are currently in the middle of a major shift in the “standard of care.” New research has introduced powerful immunotherapy options and a move toward more conservative, “lung-sparing” surgeries ^[1][2].

The Rise of Immunotherapy

If a tumor is unresectable (meaning it cannot be safely removed by a surgeon), the first-line treatment used to be chemotherapy alone. Today, immunotherapy—which uses your own immune system to fight the cancer—is a primary option ^[1].

• CheckMate 743 (The Dual-Immunotherapy Standard): This landmark clinical trial proved that a combination of two immunotherapy drugs, nivolumab and ipilimumab, worked better than traditional chemotherapy for many patients ^[1]. The study showed that at five years, the survival rate for those on immunotherapy was 14%, compared to just 6% for those on chemotherapy ^[1].

Managing Side Effects of Systemic Therapy

While immunotherapy is a massive leap forward, it is not without risks. Because it hyper-activates the immune system, the body can sometimes attack its own healthy organs ^[1][3]. It is critical to report these immune-mediated adverse events to your doctor immediately:

• Colitis: Severe diarrhea or abdominal pain ^[1].
• Pneumonitis: New or worsening cough and shortness of breath ^[1].
• Hepatitis: Liver inflammation, often noticed as yellowing of the skin or eyes ^[1].

Chemotherapy (like pemetrexed) is still heavily used and has its own side effects, typically including nausea, fatigue, and a drop in blood cell counts (increasing infection risk) ^[4].

Shifting Surgical Guidelines

When surgery is an option, there has been a long-standing debate between two procedures. In modern medicine, the trend is moving toward less radical, “lung-sparing” approaches ^[5].

1. Pleurectomy/Decortication (P/D): This is a lung-sparing surgery where the surgeon removes the diseased lining (the pleura) and all visible tumor but leaves the lung itself intact ^[2].
2. Extrapleural Pneumonectomy (EPP): This is a radical surgery where the surgeon removes the entire lung, the lining, part of the diaphragm, and the lining of the heart ^[2].

Why P/D is now preferred: Modern guidelines increasingly favor P/D ^[5]. Because P/D leaves the lung in place, it is generally safer, has lower rates of complications, and allows for a much better quality of life after surgery compared to EPP ^[6]. EPP is falling out of favor because it is highly taxing and does not always provide a survival benefit over the less invasive P/D ^[6].

Can I Have Surgery AND Immunotherapy?

Many patients wonder if they can have a lung-sparing surgery and the new immunotherapy drugs. While the standard practice has kept them separate (surgery for early stage, immunotherapy for advanced stage), combining them is currently a major focus of clinical trials ^[7]. Some centers are testing immunotherapy before surgery (neoadjuvant) to shrink the tumor. Because treatment is so personalized, it is essential that your care plan is coordinated by a multidisciplinary team ^[8].